Drug intelligence / Profile preview

FestiGel

Development stage: Preclinical
Lead developer: GN Corporation
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Implant

Overview

FestiGel (Free-from-Endotoxin-excess-Scaffold of Thermoresponsive Intelli-GEL) is a synthetic thermoresponsive hydrogel scaffold developed by GN Corporation and Nichi Glucan. It is designed to provide a low-endotoxin matrix for regenerative medicine applications, serving as a structural support for cell growth and tissue engineering. The material's thermoresponsive nature allows it to transition between states based on temperature, facilitating its application in clinical settings. It is currently in the preclinical stage of development, with the regulatory approval process for medical devices underway.

Brand names: FestiGel
Other names: Free-from-Endotoxin-excess-Scaffold of Thermoresponsive Intelli-GEL

Beyond the preview

Go deeper on FestiGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FestiGel.

Explore the full profile